Protein kinase research presents an opportunity to explore molecular targets in the body to treat diseases like cancer and ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...

A few years earlier I'd helped show that a phosphatidylinositol (PI) kinase activity copurified with various oncoprotein tyrosine kinases, and that this association was critical for the ability of ...

Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous ...

Protein kinase inhibitors have revolutionized cancer treatment by targeting specific kinases involved in tumor growth and survival. As of 2024, over 80 small-molecule protein kinase inhibitors have ...

Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Thymidine Kinase 2 Deficiency - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The ...

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...